292 related articles for article (PubMed ID: 21598242)
1. Cost-effectiveness of combination versus sequential docetaxel and carboplatin for the treatment of platinum-sensitive, recurrent ovarian cancer.
Havrilesky LJ; Pokrzywinski R; Revicki D; Higgins RV; Nycum LR; Kohler MF; Berchuck A; Myers ER; Secord AA
Cancer; 2012 Jan; 118(2):386-91. PubMed ID: 21598242
[TBL] [Abstract][Full Text] [Related]
2. A multicenter, randomized, phase 2 clinical trial to evaluate the efficacy and safety of combination docetaxel and carboplatin and sequential therapy with docetaxel then carboplatin in patients with recurrent platinum-sensitive ovarian cancer.
Alvarez Secord A; Berchuck A; Higgins RV; Nycum LR; Kohler MF; Puls LE; Holloway RW; Lewandowski GS; Valea FA; Havrilesky LJ
Cancer; 2012 Jul; 118(13):3283-93. PubMed ID: 22072307
[TBL] [Abstract][Full Text] [Related]
3. Health-related quality of life outcomes of docetaxel/carboplatin combination therapy vs. sequential therapy with docetaxel then carboplatin in patients with relapsed, platinum-sensitive ovarian cancer: results from a randomized clinical trial.
Pokrzywinski R; Secord AA; Havrilesky LJ; Puls LE; Holloway RW; Lewandowski GS; Higgins RV; Nycum LR; Kohler MF; Revicki DA
Gynecol Oncol; 2011 Dec; 123(3):505-10. PubMed ID: 21945310
[TBL] [Abstract][Full Text] [Related]
4. At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis.
Cohn DE; Kim KH; Resnick KE; O'Malley DM; Straughn JM
J Clin Oncol; 2011 Apr; 29(10):1247-51. PubMed ID: 21383297
[TBL] [Abstract][Full Text] [Related]
5. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
[TBL] [Abstract][Full Text] [Related]
6. An economic analysis of dose dense weekly paclitaxel plus carboplatin versus every-3-week paclitaxel plus carboplatin in the treatment of advanced ovarian cancer.
Dalton HJ; Yu X; Hu L; Kapp DS; Benjamin I; Monk BJ; Chan JK
Gynecol Oncol; 2012 Feb; 124(2):199-204. PubMed ID: 22055763
[TBL] [Abstract][Full Text] [Related]
7. PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.
Smith HJ; Walters Haygood CL; Arend RC; Leath CA; Straughn JM
Gynecol Oncol; 2015 Oct; 139(1):59-62. PubMed ID: 26303225
[TBL] [Abstract][Full Text] [Related]
8. Management of platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.
Havrilesky LJ; Secord AA; Kulasingam S; Myers E
Gynecol Oncol; 2007 Nov; 107(2):211-8. PubMed ID: 17870150
[TBL] [Abstract][Full Text] [Related]
9. Economic impact of paclitaxel shortage in patients with newly diagnosed ovarian cancer.
Havrilesky LJ; Garfield CF; Barnett JC; Cohn DE
Gynecol Oncol; 2012 Jun; 125(3):631-4. PubMed ID: 22446408
[TBL] [Abstract][Full Text] [Related]
10. Cost effectiveness of alternative strategies for incorporating bevacizumab into the primary treatment of ovarian cancer.
Barnett JC; Alvarez Secord A; Cohn DE; Leath CA; Myers ER; Havrilesky LJ
Cancer; 2013 Oct; 119(20):3653-61. PubMed ID: 23921967
[TBL] [Abstract][Full Text] [Related]
11. Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: a cost-effectiveness analysis.
Bristow RE; Santillan A; Salani R; Diaz-Montes TP; Giuntoli RL; Meisner BC; Armstrong DK; Frick KD
Gynecol Oncol; 2007 Sep; 106(3):476-81. PubMed ID: 17688927
[TBL] [Abstract][Full Text] [Related]
12. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.
Vasey PA; Jayson GC; Gordon A; Gabra H; Coleman R; Atkinson R; Parkin D; Paul J; Hay A; Kaye SB;
J Natl Cancer Inst; 2004 Nov; 96(22):1682-91. PubMed ID: 15547181
[TBL] [Abstract][Full Text] [Related]
13. Cost-utility analysis of platinum-based chemotherapy versus taxane and other regimens for ovarian cancer.
Lairson DR; Parikh RC; Cormier JN; Du XL
Value Health; 2014; 17(1):34-42. PubMed ID: 24438715
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: modeling the downstream effects.
Au HJ; Golmohammadi K; Younis T; Verma S; Chia S; Fassbender K; Jacobs P
Breast Cancer Res Treat; 2009 Apr; 114(3):579-87. PubMed ID: 18443903
[TBL] [Abstract][Full Text] [Related]
15. A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer.
Montero AJ; Avancha K; Glück S; Lopes G
Breast Cancer Res Treat; 2012 Apr; 132(2):747-51. PubMed ID: 22200867
[TBL] [Abstract][Full Text] [Related]
16. Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation.
Edwards SJ; Barton S; Thurgar E; Trevor N
Health Technol Assess; 2015 Jan; 19(7):1-480. PubMed ID: 25626481
[TBL] [Abstract][Full Text] [Related]
17. Capecitabine plus docetaxel combination therapy.
Verma S; Maraninchi D; O'Shaughnessy J; Jamieson C; Jones S; Martín M; McKendrick J; Miles D; Twelves C; Hornberger J
Cancer; 2005 Jun; 103(12):2455-65. PubMed ID: 15892043
[TBL] [Abstract][Full Text] [Related]
18. A cost-utility analysis of NRG Oncology/Gynecologic Oncology Group Protocol 218: incorporating prospectively collected quality-of-life scores in an economic model of treatment of ovarian cancer.
Cohn DE; Barnett JC; Wenzel L; Monk BJ; Burger RA; Straughn JM; Myers ER; Havrilesky LJ
Gynecol Oncol; 2015 Feb; 136(2):293-9. PubMed ID: 25449568
[TBL] [Abstract][Full Text] [Related]
19. Adding bevacizumab to single agent chemotherapy for the treatment of platinum-resistant recurrent ovarian cancer: A cost effectiveness analysis of the AURELIA trial.
Wysham WZ; Schaffer EM; Coles T; Roque DR; Wheeler SB; Kim KH
Gynecol Oncol; 2017 May; 145(2):340-345. PubMed ID: 28291545
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of docetaxel and carboplatin in recurrent platinum-sensitive ovarian, peritoneal and tubal cancer.
Strauss HG; Henze A; Teichmann A; Karbe I; Baumgart A; Thomssen C; Koelbl H
Gynecol Oncol; 2007 Mar; 104(3):612-6. PubMed ID: 17069876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]